Acurx Pharmaceuticals, Inc., a late-stage biopharmaceutical company, announced the publication of its Phase 2b clinical trial results in Lancet Microbe. The study evaluated the efficacy, safety, pharmacokinetics, and associated microbiome changes of its lead antibiotic candidate, ibezapolstat, compared to vancomycin in adults with Clostridioides difficile infection $(CDI.NZ)$. The results indicated that 94% of patients in the ibezapolstat group experienced a clinical cure, with 100% remaining free of CDI recurrence one month after the end of treatment. In contrast, 14% of patients treated with oral vancomycin experienced recurrent infection. The findings, combined with previous Phase 2a results, support ibezapolstat's potential as a transformative treatment for CDI. Acurx is preparing to advance to international Phase 3 clinical trials.